FLT3 and acute myeloid leukemia: We studied the biological effects of what are, to our knowledge, 2 novel FLT3 inhibitors, HSN608 and HSN748, on primary de novo AML, drug resistant AML, and relapsed/refractory AML with FLT3 mutations.